C2N Diagnostics, LLC, a specialty diagnostics company, has received a $10 million investment from Samsung C&T Corporation, Samsung Biologics, Samsung Bioepis, and Samsung Venture Investment Corporation—bolstering its ability to further scale its clinical laboratory services and advanced diagnostic solutions in the field of brain health.

Dr. Joel Braunstein, CEO of C2N, said, “Samsung is an international leader and widely recognized for the seriousness and thorough reviews it undertakes in its strategic decisions. We greatly appreciate the confidence Samsung brings to this partnership as we believe it affirms the value and quality of our advanced diagnostic solutions. Samsung’s important investment will allow C2N to further strengthen our capabilities, expand our commercial scale, and innovate next generation diagnostic tests that can improve patients’ lives.”

Jaywoo Kim, Executive Vice President of Samsung C&T Corporation, said, “We are confident that C2N Diagnostics will further grow its leading position in the industry by serving global biopharma customers as well as medical service providers with its well-established blood biomarker testing portfolio.”

Through this strategic investment, C2N aims to continue accelerating organizational capabilities to ensure patients globally have access to C2N’s blood biomarker testing technologies for Alzheimer’s disease and related dementias.

The Journal of the American Medical Association (JAMA) recently published a clinical study examining the ability of C2N’s PrecivityAD2 blood test algorithm to improve the diagnostic accuracy of Alzheimer’s disease in primary care settings. The study found similar robustness of test performance in patients who saw memory care specialists. The PrecivityAD2 test result delivered a highly statistically significant accuracy of over 90% at a pre-defined, single binary cutoff compared to cerebrospinal fluid (CSF) analysis or amyloid PET analysis.

C2N is now expanding the biomarker pipeline by developing advanced assays targeting tau pathology, Parkinson’s disease research, and developing technologies to decentralize mass spectrometry testing.